Through
11/26
A complete list of stories featured on Penn Today.
News・ Arts, Humanities, & Social Sciences
In his dissertation research, joint communication and political science doctoral student Nicholas Dias searches for new ways to gauge voter competency.
News・ Campus & Community
In conversation with Professor of Practice Ben Jealous, neuroscience professor Peter Sterling returned to campus to talk about activism in his youth and how that informed his research in health.
News・ Arts, Humanities, & Social Sciences
A study led by Desmond Patton utilizes social work, communications, and data science to explore how gang-affiliated Black youth use Twitter content, photos, and emojis to memorialize the deceased and navigate feelings of grief and loss.
News・ Arts, Humanities, & Social Sciences
Sociology Ph.D. candidate Olivia Hu is studying how people choose romantic partners across race lines, and how those relationships affect their understandings of social difference.
News・ Arts, Humanities, & Social Sciences
Three experts from around the University share their thoughts on what Navalny’s death means for the opposition movement, for Putin’s grip on power, and for Russia going forward.
News・ Campus & Community
Through “Ukraine: The Edge of Freedom,” Penn Live Arts presents performances that uplift the culture of a nation during a time of war.
News・ Science & Technology
A new silicon-photonic (SiPh) chip design from the lab of Nader Engheta, alongside Firooz Aflatouni, uses light waves, the fastest possible means of communication, rather than electricity, to perform mathematical computations.
News・ Arts, Humanities, & Social Sciences
With the two-year anniversary of the Russian full-scale invasion of Ukraine looming, city planners begin to strategize solutions to rebuild, sustainably.
News・ Health Sciences
Iris Reyes, who founded the Alliance of Minority Physicians in 2012, is working to expand the program to underrepresented students and professionals across the region.
News・ Science & Technology
Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.